Epithelial Ovarian Cancer

**CLINICAL PRESENTATION**
- Pelvic Mass
- Diagnosis by previous surgery

**INITIAL EVALUATION**
- CXR
- Verify most recent mammogram
- CA125
- Ultrasound or CT of abdomen and pelvis if suspicion of cancer
- Barium enema if clinically indicated

**PRIMARY TREATMENT**
- Laparotomy/TAH/BSO with comprehensive staging, or
  - If Stage I, Grade 1 and patient desires fertility - USO and staging biopsies, or
  - If Stage III or IV and medically stable - cytoreductive surgery, or
  - If patient unable to tolerate surgery, consider chemotherapy.

**PATHOLOGIC STAGE**
- Stage Ia or Ib
- Stage Ic

**PRIMARY ADJUVANT THERAPY**
- Cispatin with cytopan x6
- Paclitaxel with carboplatin for 6 cycles or
- Paclitaxel with cispatin for 6 cycles
- Single-agent carboplatin

**SURVEILLANCE**
- Visits every 3 mo for 4 visits, then every 4 mo for 3 visits, then every 6 mo for 6 visits
- Physical and pelvic exam every visit
- CT of abdomen and pelvis or CXR if indicated by signs or symptoms - not routine

**PATHOLOGIC STAGE**
- Grade 1 (Low grade)
- Grade 2 or 3 (High grade)

**Note:** See Consolidation on page 2
Epithelial Ovarian Cancer

**Consolidation Treatment**

- **Stage III and IV complete remission**
  - Observe or 2nd-look surgery (laparoscopy or laparotomy)
  - Clinical Trial
  - Surveillance as for Stage I and II

- **Stage III and IV partial remission**
  - Clinical trial or
  - Continue paclitaxel or carboplatin or
  - Hormonal therapy (tamoxifen)
  - Surveillance*

**Relapse or Progression**

- **Stage I and II relapse or progression**
  - Clinical relapse
    - Scans as indicated
    - Residual disease
    - Yes → Laparotomy or cytoreductive surgery followed by chemotherapy
    - No → Surveillance*
  - Rising CA125 only
    - Clinical trial or
    - Chemotherapy/hormonal therapy or
    - Initiate salvage therapy when clinical disease apparent
    - Individualize surveillance as appropriate

- **Stage III and IV disease progression**
  - Cytoreductive surgery
  - Cytoxan and cisplatin or paclitaxel and cisplatin or paclitaxel and carboplatin
  - Clinical trial or
    - Best Supportive Care
    - Hormonal therapy (tamoxifen)
  - Yes → Surveillance pending tumor status*
  - No → Residual disease?
    - Yes → Surveillance pending tumor status*
    - No → Options based on performance status and primary therapy:
      - Paclitaxel and platinum-based treatment
      - Paclitaxel
      - Carboplatin
      - Clinical trial
      - Secondary cytoreductive surgery or consider chemotherapy or clinical trials

**Salvage**

- **No previous chemotherapy**
  - Cytoreductive surgery
  - Watch or second-look surgery (laparoscopy or laparotomy)
  - Clinical Trial

- **No response or progression on primary chemo or relapse <6 mo after stopping chemo (paclitaxel & cisplatin resistant)**
  - Cytoreductive surgery
  - Options based on performance status and primary therapy:
    - Paclitaxel and platinum-based treatment
    - Paclitaxel
    - Carboplatin
    - Clinical trial
  - Yes → Surveillance pending tumor status*
  - No → Residual disease?
    - Yes → Surveillance pending tumor status*
    - No → Options based on performance status and primary therapy:
      - Paclitaxel and platinum-based treatment
      - Paclitaxel
      - Carboplatin
      - Clinical trial
      - Secondary cytoreductive surgery or consider chemotherapy or clinical trials

*Refer to Surveillance as shown on Page 1